top of page
Developing Fluorescent Biomarkers to Improve
Our Mission: To become the world leader in fluorescence based diagnostics and surgical support.
Cancer removal is challenging ...
... and incomplete removal leads to recurrence.
Reiner et al. Neoplasia 2012, 14:169–17.
But using fluorescent biomarkers allows clinicians to more effectively find and remove cancer.
Our proprietary technology is a fluorescent small molecule, PARPi-FL, that detects overexpression of PARP, a DNA repair enzyme, which is common in many cancers. Thus, our technology specifically targets oral cancer, enabling earlier, more accurate detection.
Summit is developing fluorescent biomarkers that target PARP, an enzyme that is over expressed by many cancers.
Tang et al. (2017) PNAS and unpublished data.
Thurber et al. Nat Commun 2013, 4, 1504.
Initial development targets:
PARPi-FL for margin detection (head & neck, cervical, skin, colorectal)
SBI-002 for fluorescence guided surgery (breast)
bottom of page